Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA’s Naloxone Product Approval Standards May See Changes

Executive Summary

Advisory committees will weigh adequacy of current pharmacokinetic requirements and pediatric dosing for novel formulations of the opioid overdose reversal agent.

You may also be interested in...



Complex Generics: Gottlieb Eyes FDA Policy Changes To Speed Approvals

US agency could reconsider requirement that instructions for use be same for branded and generic products, FDA Commissioner-nominee Scott Gottlieb suggests, while also leaving door open to statutory changes in Hatch-Waxman Act.

Complex Generics: Gottlieb Eyes FDA Policy Changes To Speed Approvals

US agency could reconsider requirement that instructions for use be same for branded and generic products, FDA Commissioner-nominee Scott Gottlieb suggests, while also leaving door open to statutory changes in Hatch-Waxman Act.

'Repeal And Replace' Going Relatively Well For Pharma So Far

US White House game plan for repealing and replacing the Affordable Care Act includes a proposal for faster generic drug approvals but no direct government price controls.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS119251

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel